EMA joins FDA in wanting more Heplisav data

Dynavax Technologies has had to withdraw its European marketing authorization application for its investigational hepatitis B vaccine Heplisav after all.

Dynavax Technologies has had to withdraw its European marketing authorization application for its investigational hepatitis B vaccine Heplisav after all.

It said the day 180 List of Outstanding Issues provided by the EMA indicated that the current Heplisav safety database...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category